Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden
Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden
- Disease:Gastroenteropancreatic neuroendocrine tumour disease
- Substances:DimeticoneLysine Hydrochloride+6
France- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Dimeticone










